RJA
PODD icon

Raymond James & Associates’s Insulet PODD Stock Holding History

Raymond James & Associates’s Portfolio PODD Stock Details PODD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$8.72M Buy
37,456
+1,367
+4% +$281K 0.01% 1304
2024
Q2 		$7.28M Sell
36,089
-3,151
-8% -$568K ﹤0.01% 1347
2024
Q1 		$6.73M Sell
39,240
-10,460
-21% -$1.95M ﹤0.01% 1387
2023
Q4 		$10.8M Sell
49,700
-6,515
-12% -$1.12M 0.01% 1062
2023
Q3 		$8.97M Buy
56,215
+2,041
+4% +$457K 0.01% 1096
2023
Q2 		$15.6M Sell
54,174
-4,372
-7% -$1.33M 0.01% 820
2023
Q1 		$18.7M Buy
58,546
+1,405
+2% +$416K 0.02% 714
2022
Q4 		$16.8M Sell
57,141
-279
-0.5% -$76.9K 0.02% 745
2022
Q3 		$13.2M Sell
57,420
-2,309
-4% -$578K 0.01% 812
2022
Q2 		$13M Buy
59,729
+3,158
+6% +$718K 0.01% 821
2022
Q1 		$15.1M Buy
56,571
+20,097
+55% +$4.93M 0.01% 849
2021
Q4 		$9.71M Buy
36,474
+12,488
+52% +$3.62M 0.01% 1123
2021
Q3 		$6.82M Sell
23,986
-3,478
-13% -$992K 0.01% 1291
2021
Q2 		$7.54M Buy
27,464
+3,933
+17% +$1.07M 0.01% 1227
2021
Q1 		$6.14M Sell
23,531
-1,462
-6% -$392K 0.01% 1298
2020
Q4 		$6.39M Sell
24,993
-9,966
-29% -$2.47M 0.01% 1195
2020
Q3 		$8.27M Sell
34,959
-803
-2% -$169K 0.01% 958
2020
Q2 		$6.95M Buy
35,762
+316
+0.9% +$60.4K 0.01% 1010
2020
Q1 		$5.87M Buy
35,446
+5,926
+20% +$1.08M 0.01% 961
2019
Q4 		$5.05M Buy
29,520
+7,282
+33% +$1.21M 0.01% 1241
2019
Q3 		$3.67M Buy
22,238
+6,479
+41% +$911K 0.01% 1410
2019
Q2 		$1.88M Sell
15,759
-352
-2% -$36.1K ﹤0.01% 1839
2019
Q1 		$1.53M Buy
16,111
+8,417
+109% +$721K ﹤0.01% 1942
2018
Q4 		$610K Sell
7,694
-274
-3% -$23.2K ﹤0.01% 2416
2018
Q3 		$844K Sell
7,968
-29,654
-79% -$2.78M ﹤0.01% 2362
2018
Q2 		$3.22M Buy
37,622
+31,479
+512% +$2.82M 0.01% 1451
2018
Q1 		$532K Buy
+6,143
New +$477K ﹤0.01% 2526
2014
Q1 		– Sell
-75,889
Closed -$2.81M – 2120
2013
Q4 		$2.81M Buy
75,889
+23,063
+44% +$852K 0.02% 785
2013
Q3 		$1.91M Sell
52,826
-12,308
-19% -$413K 0.02% 908
2013
Q2 		$2.05M Buy
+65,134
New +$1.85M 0.02% 800

Other funds holding PODD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Raymond James & Associates's PODD Position: Q3 2024 in Review

Raymond James & Associates increased its Insulet (PODD) stake by 3.8% in Q3 2024, buying an estimated $281K and bringing the position to 37,456 shares worth $8.72M. The position accounts for 0.01% of the portfolio, ranked #1304.

Raymond James & Associates first reported a position in PODD in Q2 2013 and has held it in 30 quarters since. The position peaked at $18.7M in Q1 2023. 623 funds tracked by Wall St. Rank hold PODD as of Q3 2024.

  • Raymond James & Associates held 37,456 shares of Insulet worth $8.72M as of Q3 2024.
  • Raymond James & Associates bought 1,367 Insulet shares in Q3 2024, an estimated $281K.
  • Insulet made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1304 holding.
  • Raymond James & Associates first reported a position in Insulet in Q2 2013 and has held it in 30 quarters since.
  • Raymond James & Associates's Insulet position peaked at $18.7M in Q1 2023.
  • 623 funds tracked by Wall St. Rank held Insulet as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.